Pamungkas Bagus Satriyo

Pamungkas Bagus Satriyo

Auto-generated profile, based on publicly available information

Pamungkas Bagus Satriyo

Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nurses, Gadjah Mada University, Yogyakarta, Indonesia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Cancer Research and Practice
Verified
Journal Article
Open access
PDF file
TCTsu- Yi Chao
Tsu- Yi Chao
PSPamungkas Bagus Satriyo
Pamungkas Bagus Satriyo
Chi-Tai YehChi-Tai Yeh
Chi-Tai Yeh
JCJia-Hong Chen
Jia-Hong Chen
TATeguh Aryandono
Teguh Aryandono
SHSofia Mubarika Haryana
Sofia Mubarika Haryana
Objective: Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen receptors (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu). Only 30% of TNBC patients show a pathologic complete response, and the other 70% of patients exhibit a less pronounced response followed by relapse and metastasis to distant organs after neoadjuvant chemotherapy. Achievements of immunotherapy targeting programmed cell death 1 ligand 1 (PD-L1) in clinical trials for treating melanoma, nonsmall-cell lung cancer, renal cell carcinoma, and TNBC suggest that targeting the interaction of tumor cells with tumor microenvironment is highly beneficial for cancer treatment. Finding a novel dual-targeting therapy against tumor cells and the tumor microenvironment (TME) may provide options for improved responses in TNBC patients. Data Sources: We searched the potential targeted therapy candidates that regulate tumor cells as well as the TME of cancer diseases, including TNBC, based on our previous and recent other publications. Study Selection: We selected the potential targeted therapies supported by relevance clinical data, in vitro and in vivo studies. Results: In this review, we found the KDM5B, Cadherin 11, β-catenin, CDK2, signal peptide CUB-EGF domain-containing protein 2, and PDL1 regulate the tumor cells and TME of TNBC cells. In addition, we also highlighted the Antrocin, Ovatodiolide, and Pterostilbene as natural small compound possess anti-cancer through the disruption of tumor cell–TME interactions. Conclusion: The new therapy approach targeting tumor cells-TME interaction may improve the response and survival rate of TNBC patients. Later, natural small compounds could provide alternative therapy options for TNBC patients.

1 July 2023 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
HWhesti lina wiraswati
hesti lina wiraswati
MBM. Hasan Bashari
M. Hasan Bashari
NANayla Majeda Alfarafisa
Nayla Majeda Alfarafisa
IMIlma Fauziah Ma'ruf
Ilma Fauziah Ma'ruf
ESEti Nurwening Sholikhah
Eti Nurwening Sholikhah
EDEma Damayanti
Ema Damayanti
J. Pharm. Pharmacogn. Res., vol. 11, no. 4, pp. 699-713, Jul-Aug 2023. DOI: https://doi.org/10.56499/jppres23.1591_11.4.699 Original Article Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors [Detección virtual de la actividad anticancerígena de las chalconas y las pirazolinas como posibles inhibidores de EGFR, VEGFR y citocromo P450] Hesti Lina Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors.

31 March 2026 in Indonesian Journal of Biotechnology
Verified
Journal Article
Open access
PDF file
JTJecklyn Shindy Temartenan
Jecklyn Shindy Temartenan
HFHairil Fiqri
Hairil Fiqri
PSPamungkas Bagus Satriyo
Pamungkas Bagus Satriyo
SMSofia Mubarika
Sofia Mubarika
Anti‐miR molecules can suppress specific microRNA (miRNA) functions within critical signaling pathways. Chitosan acts as a delivery system for miRNAs; therefore, encapsulating miR‐203a‐3p is essential for targeted delivery and biological activity. This study investigates the impact of chitosan‐encapsulated anti‐miR‐203a‐3p nanoparticles (CS‐NPs) on the viability, proliferation, and migration of triple‐negative breast cancer (TNBC) 4T1 cells. The nanoparticles were synthe‐ sized using the ionic gelation method in a 5:1 ratio of chitosan to anti‐miR‐203a‐3p, incorporating sodium tripolyphosphate (STPP) as a crosslinker. Characterization was conducted using gel electrophoresis and particle size analysis. Cytotoxicity and cell viability were assessed through the MTT assay, while colony formation and wound healing assays evaluated cell proliferation and migration. The nanoparticles demonstrated an encapsulation efficiency of 89.47% and showed significant inhibitory effects on 4T1 cell proliferation and migration. The MTT results indicate an IC50 value of 2.454 µM, while colony formation analysis revealed that both ½ and IC50 doses significantly reduced colony numbers compared to the control. Similarly, wound healing assays showed notable inhibition of cell migration at ¼, ½, and IC50 concentrations. These findings suggest that anti‐miR‐203a‐3p‐loaded CS‐NPs may offer a promising therapeutic approach to managing aggressive breast cancer subtypes, particularly TNBC.

23 May 2026 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Closed access
SASyamsul Arif Ardiansyah
Syamsul Arif Ardiansyah
SMSofia Mubarika
Sofia Mubarika
HNHabibullah Noficandra
Habibullah Noficandra
PSPamungkas Bagus Satriyo
Pamungkas Bagus Satriyo
DNDwi Aris Agung Nugrahaningsih
Dwi Aris Agung Nugrahaningsih
Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking targeted therapy options. MicroRNA-based therapy, particularly hsa-miR-203a-3p, has shown tumor-suppressive potential; however, an effective delivery system is required to enhance its stability and cellular uptake. Exosomes represent a promising natural carrier for miRNA delivery. Methods: Exosomes derived from UC-MSCS secretome were isolated and characterized using Nanoparticle Tracking Analysis (NTA). Exosome-loaded hsa-miR-203a-3p (ExomiR) was generated using the Exo-Fect transfection system. Functional assays, including MTT and wound-healing assays, were performed on TNBC Hs578T cells. qRT-PCR was used to measure miRNA uptake. In silico analysis utilizing TargetScan, TarBase, DAVID, and the TNBC dataset GSE65194 was performed to identify target genes and pathways. Results: ExomiR significantly reduced TNBC cell viability in a dose-dependent manner, with viability dropping below 50% at the 2× dose. Migration assays showed the strongest inhibition at 1× dose at 12 hours (37.4±13%, p<0.01) and at 2× dose at 24 hours (32.3±6.18%, p<0.0001). ExomiR treatment yielded an 87-fold increase in intracellular hsa-miR-203a-3p expression. In silico analysis identified 23 upregulated TNBC-related target genes, including CCNB1 and CDK1, which regulate cell cycle, p53 signaling, and cellular senescence pathways. Conclusion: Exosome-mediated delivery enhances hsa-miR-203a-3p uptake and effectively suppresses cell viability and migration in TNBC cells. Computational analysis further indicates that hsa-miR-203a-3p regulates key oncogenic pathways, supporting its potential as a therapeutic agent.